FHM V, LP
CIK 1346948 · last filed 2017-02-06
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
CADX price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
SEATTLE, WA 98101
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ANAB | 10%+ Owner | 2,345,612 | $48.77 | $114.40M | $0 | 1 | 2017-02-06 |
| Zeltiq Aesthetics Inc (ZLTQ) Delisted | 10%+ Owner | 4,427,244 | — | — | $0 | 2 | 2013-09-24 |
| LA JOLLA PHARMACEUTICAL CO (LJPC) Delisted | 10%+ Owner | 109,411 | $6.22 | $680.5K | $14.64M | 2 | 2009-02-26 |
| CADENCE PHARMACEUTICALS INC (CADX) Delisted | 10%+ Owner | 7,848,501 | — | — | $446.09M | 1 | 2009-02-20 |
| AMICUS THERAPEUTICS, INC. (FOLD) Delisted | 10%+ Owner | 767,618 | $14.49 | $11.12M | $14.62M | 8 | 2008-03-05 |
| ENDOCARE INC (ENDO) Delisted | 10%+ Owner | 1,716,331 | — | — | $3.19M | 3 | 2008-01-31 |
Recent Filings · Page 2 of 2
17 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2008-02-04 | AMICUS THERAPEUTICS, INC. (FOLD) Delisted | Buy (P) | +172,200 | $1.65M | EDGAR |
| 2008-01-31 | ENDOCARE INC (ENDO) Delisted | Buy (P) | +17,052 | $118.5K | EDGAR |
| 2008-01-28 | ENDOCARE INC (ENDO) Delisted | Buy (P) | +56,004 | $357.9K | EDGAR |
| 2007-12-13 | ENDOCARE INC (ENDO) Delisted | Buy (P) | +350,001 | $2.71M | EDGAR |
| 2007-08-10 | AMICUS THERAPEUTICS, INC. (FOLD) Delisted | Buy (P) | +177,600 | $2.04M | EDGAR |
| 2007-07-02 | AMICUS THERAPEUTICS, INC. (FOLD) Delisted | Buy (P) | +109,086 | $1.25M | EDGAR |
| 2007-04-09 | LA JOLLA PHARMACEUTICAL CO (LJPC) Delisted | Buy (P) | +2,499,999 | $15.00M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.